CENCORA INC (COR) Stock News
NYSE:COR - New York Stock Exchange, Inc. - US03073E1055 - Common Stock - Currency: USD
COR Latest News, Press Relases and Analysis
Top S&P500 movers in Thursday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Smart Beta ETF report for RSPH
ECL Stock Gains Following Latest Launch to Boost Data Center Cooling
Ecolab's 3D TRASAR technology expands its cooling solutions, aiming to optimize data centers and cut resource demand.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
Smart Beta ETF report for EUSA
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Mentions: CPRX
Charles River Stock May Gain From Extended CHDI Research Deal on HD
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
Beat the Market the Zacks Way: GE Aerospace, Monster Beverage, Cencora in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
Style Box ETF report for IWP
Here's Why Investors Should Consider Retaining Danaher Stock Now
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Sector ETF report for RSPH
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Is Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) a Strong ETF Right Now?
Smart Beta ETF report for FLQM
Robust Results Lifted Cencora (COR) Amid Upgraded Outlook
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The broad-based downturn in US equities underperformed overseas markets in the first quarter. In this negative environment, the strategy outperformed the index in the first quarter. The […]
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.